RISE: Reporting and Intervention for Stars Excellence

Improve and Maintain Star Ratings

RISE is a comprehensive Star Ratings Improvement program that focuses on positive outcomes for Medicare Part D (Part D) clinical measures, including:

  • Medication adherence for diabetes medications
  • Medication adherence for hypertension (RAS antognists)
  • Medication adherence for cholesterol (SUPD)
  • Polypharmacy: Use of multiple anticholinergic medications in older adults (Poly-ACH)
  • Concurrent use of opioids and benzodiazepines
4 to 6 percentage point increase in each adherence measure. Performance increase in 2023 versus 2022 for a DSNP client.

Combined, these measures comprise a large proportion of the Part D Star Ratings calculation and heavily influence the largest weighted measure: Drug Plan Quality Improvement. When paired with our Medication Therapy Management (MTM) program, health plans have the opportunity to provide comprehensive clinical support to their members to improve outcomes, reduce cost and improve Star Ratings.

“It is our passion to improve Star Ratings through clinical interventions, and our privilege to walk with members on their unique health journeys.”
Amanda Lee, PharmD, Clinical Program Manager

Our Proprietary Application

RISE’s proprietary, web-based application performs three core functions: automated daily qualification, clinical intervention and on demand reporting. It is easy to use and its customizable settlings allow health plans to delegate interventions to the Navitus Clinical Engagement Center, complete interventions on their own using out software or use a hybrid access model.

The on-demand reporting feature includes near real-time data for unparallelled insight into plan goal progress. The analytics identify interventions to target members most in need of support. Our demonstrated results prove that interventions completed maximize Star Ratings impact.

Take the Next Step

Email us at [email protected] for more information about RISE or to set up a demonstration.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

previous arrow
next arrow